Development of pectin matrix tablets for colonic delivery of model drug ropivacaine

被引:92
作者
Ahrabi, SF
Madsen, G
Dyrstad, K
Sande, SA
Graffner, C
机构
[1] Univ Oslo, Sch Pharm, Dept Pharmaceut, N-0316 Oslo, Norway
[2] Nycomed Imaging AS, R&D, Oslo, Norway
[3] Med Prod Agcy, Uppsala, Sweden
关键词
pectins; ethylcellulose; matrix tablet; colonic delivery; pH-dependent coating; in vitro dissolution; multivariate analysis;
D O I
10.1016/S0928-0987(99)00087-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this work was to develop pectin-based matrix tablets for colonic delivery of the model drug ropivacaine, with the future perspective of radiolabelling the system by neutron activation technique for a gamma-scintigraphic study. The aim was to investigate some formulation factors that could reduce the release of the drug in the simulated gastric and intestinal fluids, increase the release in the simulated cecal fluid (with pectinolytic enzymes) and improve the poor compactibility of pectins. For dissolution studies, the flow-through apparatus with sequential dissolution liquids simulating the mouth-to-colon conditions was used. The effect of two pectin types, the incorporation of ethylcellulose as a dry matrix-additive and water or ethanol as granulation liquids were investigated in a study designed as a D-optimal mixture. Amidated pectin (Am.P) produced harder tablets than the calcium salt of pectin (Ca.P) and was more susceptible to enzymatic degradation. Addition of ethylcellulose increased the tablet strength and the dissolution rate. Furthermore, directly compressed Am.P tablets were produced by addition of coarse or micronised qualities of ethylcellulose. The latter improved the crushing strength markedly imposing a marginal release-reducing effect. Coating this formulation with Eudragit(R) L 100 reduced the release in the simulated upper GI conditions without interference with the subsequent enzymatic activity. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:43 / 52
页数:10
相关论文
共 24 条
[1]   The use of scintigraphy to provide ''proof of concept'' for novel polysaccharide preparations designed for colonic drug delivery [J].
Adkin, DA ;
Kenyon, CJ ;
Lerner, EI ;
Landau, I ;
Strauss, E ;
Caron, D ;
Penhasi, A ;
Rubinstein, A ;
Wilding, IR .
PHARMACEUTICAL RESEARCH, 1997, 14 (01) :103-107
[2]   Influence of neutron activation factors on the physico-chemical properties of suppositories and their excipients [J].
Ahrabi, SF ;
Sande, SA ;
Waaler, T ;
Graffner, C .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 8 (03) :193-201
[3]   Effects of thermal neutron irradiation on some potential excipients for colonic delivery systems [J].
Ahrabi, SF ;
Sande, SA ;
Waaler, T ;
Graffner, C .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (04) :453-462
[4]   TARGETING DRUGS TO THE COLON - DELIVERY SYSTEMS FOR ORAL-ADMINISTRATION [J].
ASHFORD, M ;
FELL, JT .
JOURNAL OF DRUG TARGETING, 1994, 2 (03) :241-257
[5]  
AXELOS MAV, 1991, CHEM TECHNOLOGY PECT, P115
[6]   Optimization of hydrophilic matrix tablets using a D-optimal design [J].
Bodea, A ;
Leucuta, SE .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 153 (02) :247-255
[7]  
DIGENIS GA, 1991, CRIT REV THER DRUG, V7, P309
[8]   Metabolism of pectin in the gastrointestinal tract [J].
Dongowski, G ;
Anger, H .
PECTINS AND PECTINASES, 1996, 14 :659-666
[9]  
ESBENSEN K, 1994, MULTIVARIATE ANAL PR
[10]  
FLORENCE AT, 1993, PHYSICOCHEMICAL PRIN, P305